Joseph K. Belanoff, M.D., is the Chief Executive Officer and President of Corcept Therapeutics Inc., a company focused on the development and commercialization of medications for severe metabolic, oncologic, and psychiatric disorders. Dr. Belanoff has been instrumental in guiding the company since its inception, leveraging his extensive expertise in endocrinology and psychiatry. He co-founded Corcept in 1998 and has since steered the company towards significant milestones, including the approval and successful marketing of Korlym, a groundbreaking treatment for Cushing's syndrome. Prior to his role at Corcept, Dr. Belanoff completed his medical degree at the University of California, San Francisco (UCSF), where he also conducted postdoctoral research in neuroendocrinology. His academic career is marked by numerous publications and contributions to the understanding of the interplay between hormones and mental health. At Corcept, Dr. Belanoff's leadership has been pivotal in expanding the company’s research and development pipeline, with a focus on cortisol modulators for a range of diseases. Under his guidance, Corcept has grown into a recognized leader in its field, emphasizing innovation and patient-centric solutions. As CEO and President, Dr. Belanoff continues to drive Corcept’s mission to address unmet medical needs through novel therapies. His strategic vision has not only solidified the company’s position in the pharmaceutical industry but also fostered a culture of scientific excellence and ethical responsibility. Dr. Belanoff’s dedication to improving patient outcomes and advancing medical science remains at the core of his leadership at Corcept Therapeutics Inc.